66 related articles for article (PubMed ID: 18081792)
1. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Mabuchi S; Sugiyama T; Kimura T
J Gynecol Oncol; 2016 May; 27(3):e31. PubMed ID: 27029752
[TBL] [Abstract][Full Text] [Related]
3. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Okamoto A; Glasspool RM; Mabuchi S; Matsumura N; Nomura H; Itamochi H; Takano M; Takano T; Susumu N; Aoki D; Konishi I; Covens A; Ledermann J; Mezzanzanica D; Steer C; Millan D; McNeish IA; Pfisterer J; Kang S; Gladieff L; Bryce J; Oza A
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S20-5. PubMed ID: 25341576
[TBL] [Abstract][Full Text] [Related]
4. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
6. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
8. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M; Tsuda H; Sugiyama T
J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
[TBL] [Abstract][Full Text] [Related]
9. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
10. A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center.
Zheng H; Chen J; Huang J; Yi H; Zhang S; Zheng X
Transl Oncol; 2024 Apr; 42():101898. PubMed ID: 38308920
[TBL] [Abstract][Full Text] [Related]
11. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.
Kitazawa S; Chiyoda T; Nakamura K; Sakai K; Yoshihama T; Nishio H; Kobayashi Y; Iwata T; Banno K; Yamagami W; Nishihara H; Aoki D
Int J Clin Oncol; 2023 Nov; 28(11):1554-1562. PubMed ID: 37574505
[TBL] [Abstract][Full Text] [Related]
12. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
Yin M; Lu C; Zhou H; Liu Q; Yang J
BMC Womens Health; 2023 Jun; 23(1):298. PubMed ID: 37270486
[TBL] [Abstract][Full Text] [Related]
13. Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
Li R; Liu X; Song C; Zhang W; Liu J; Jiao X; Yu Y; Zeng S; Chi J; Zhao Y; Ma G; Huo Y; Li M; Peng Z; Li G; Jiang J; Gao QL
BMJ Open; 2022 May; 12(5):e058132. PubMed ID: 35613822
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY; Manning-Geist B; Gordhandas S; Murali R; Marra A; Liu YL; Friedman CF; Hollmann TJ; Zivanovic O; Chi DS; Weigelt B; Konner JA; Zamarin D
Int J Gynecol Cancer; 2022 Aug; 32(8):1017-1024. PubMed ID: 35545291
[TBL] [Abstract][Full Text] [Related]
15. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
[TBL] [Abstract][Full Text] [Related]
16. A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.
Heong V; Tan TZ; Miwa M; Ye J; Lim D; Herrington CS; Iida Y; Yano M; Yasuda M; Ngoi NY; Wong SJ; Okamoto A; Gourley C; Hasegawa K; Tan DS; Huang RY
J Pathol; 2021 Nov; 255(3):285-295. PubMed ID: 34322886
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer.
Mizuno T; Kojima Y; Yonemori K; Yoshida H; Sugiura Y; Ohtake Y; Okuma HS; Nishikawa T; Tanioka M; Sudo K; Shimomura A; Noguchi E; Kato T; Shimoi T; Uno M; Ishikawa M; Fujiwara Y; Ohe Y; Tamura K
Oncol Lett; 2020 Dec; 20(6):336. PubMed ID: 33123247
[TBL] [Abstract][Full Text] [Related]
18. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Kondo E; Tabata T; Suzuki N; Aoki D; Yahata H; Kotera Y; Tokuyama O; Fujiwara K; Kimura E; Terauchi F; Sumi T; Okamoto A; Yaegashi N; Enomoto T; Sugiyama T
J Gynecol Oncol; 2020 Nov; 31(6):e94. PubMed ID: 33078599
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
